Literature DB >> 28615731

The role of IL-6 in host defence against infections: immunobiology and clinical implications.

Stefan Rose-John1, Kevin Winthrop2, Leonard Calabrese3.   

Abstract

IL-6 is a pleiotropic cytokine with broad-ranging effects within the integrated immune response. One of the roles of IL-6 is to support immunocompetence, defined as the ability of a host to respond to infections. Understanding the precise role of this cytokine in immunocompetence requires a critical appraisal of data derived from both preclinical and clinical studies. Primary immunodeficiency diseases involving IL-6 or its signalling pathways reveal that IL-6 is critical in the defence against numerous types of pathogens. Studies of IL-6 signalling in preclinical models reveal that selective inhibition of either classic IL-6 signalling or IL-6 trans-signalling has differential effects on the host response to different types of infections. Knowledge of such variation might inform bioengineering of new IL-6-targeting molecules and potentially enable modulation of their toxicity. Clinical studies of IL-6 inhibitors, mainly tocilizumab, reveal that their use is associated with an increased rate of both serious and opportunistic infections generally in the range observed with other non-IL-6 directed biologic therapies. Targeting IL-6 has several other important clinical implications related to diagnosis, management and prevention of infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28615731     DOI: 10.1038/nrrheum.2017.83

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  123 in total

Review 1.  Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.

Authors:  John J O'Shea; Massimo Gadina; Robert D Schreiber
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

2.  The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment.

Authors:  Youichi Yanagawa; Yohei Hirano; Hiroshi Kato; Toshiaki Iba
Journal:  BMJ Case Rep       Date:  2012-05-23

3.  Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo.

Authors:  Helen L Wright; Andrew L Cross; Steven W Edwards; Robert J Moots
Journal:  Rheumatology (Oxford)       Date:  2014-03-07       Impact factor: 7.580

4.  IL-6 is required for airway mucus production induced by inhaled fungal allergens.

Authors:  Wendy A Neveu; Jenna B Allard; Oliver Dienz; Matthew J Wargo; Gennaro Ciliberto; Laurie A Whittaker; Mercedes Rincon
Journal:  J Immunol       Date:  2009-07-10       Impact factor: 5.422

Review 5.  The Ying and Yang of STAT3 in Human Disease.

Authors:  Tiphanie P Vogel; Joshua D Milner; Megan A Cooper
Journal:  J Clin Immunol       Date:  2015-08-18       Impact factor: 8.317

6.  An essential role for ectodomain shedding in mammalian development.

Authors:  J J Peschon; J L Slack; P Reddy; K L Stocking; S W Sunnarborg; D C Lee; W E Russell; B J Castner; R S Johnson; J N Fitzner; R W Boyce; N Nelson; C J Kozlosky; M F Wolfson; C T Rauch; D P Cerretti; R J Paxton; C J March; R A Black
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

7.  Janus Kinase 1 Is Essential for Inflammatory Cytokine Signaling and Mammary Gland Remodeling.

Authors:  Kazuhito Sakamoto; Barbara L Wehde; Kyung Hyun Yoo; Taemook Kim; Nirakar Rajbhandari; Ha Youn Shin; Aleata A Triplett; Patrick D Rädler; Fabian Schuler; Andreas Villunger; Keunsoo Kang; Lothar Hennighausen; Kay-Uwe Wagner
Journal:  Mol Cell Biol       Date:  2016-05-16       Impact factor: 4.272

8.  Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice.

Authors:  Vivian P Bykerk; Andrew J K Ostör; José Alvaro-Gracia; Karel Pavelka; José Andrés Román Ivorra; Winfried Graninger; William Bensen; Michael T Nurmohamed; Andreas Krause; Corrado Bernasconi; Andrea Stancati; Jean Sibilia
Journal:  Ann Rheum Dis       Date:  2012-05-21       Impact factor: 19.103

9.  Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

Authors:  Gerd R Burmester; Yong Lin; Rahul Patel; Janet van Adelsberg; Erin K Mangan; Neil M H Graham; Hubert van Hoogstraten; Deborah Bauer; Juan Ignacio Vargas; Eun Bong Lee
Journal:  Ann Rheum Dis       Date:  2016-11-17       Impact factor: 19.103

10.  Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice.

Authors:  Z Chai; S Gatti; C Toniatti; V Poli; T Bartfai
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  101 in total

1.  The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Alvise Berti; Roscoe Warner; Kent Johnson; Divi Cornec; Darrell R Schroeder; Brian F Kabat; Carol A Langford; Cees G M Kallenberg; Philip Seo; Robert F Spiera; E William St Clair; Fernando C Fervenza; John H Stone; Paul A Monach; Ulrich Specks; Peter A Merkel
Journal:  J Autoimmun       Date:  2019-07-15       Impact factor: 7.094

2.  Interaction with an endothelial lumen increases neutrophil lifetime and motility in response to P aeruginosa.

Authors:  Laurel E Hind; Patrick N Ingram; David J Beebe; Anna Huttenlocher
Journal:  Blood       Date:  2018-08-24       Impact factor: 22.113

3.  Localization of interleukin-6 signaling complex in epithelialized apical lesions of endodontic origin.

Authors:  C Schweitzer; M Garrido; R Paredes; C Stoore; M Reyes; R Bologna-Molina; A Fernández; Marcela Hernández Rios
Journal:  Clin Oral Investig       Date:  2021-01-07       Impact factor: 3.573

Review 4.  Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Qi Han; Mingyue Guo; Yue Zheng; Ying Zhang; Yanshan De; Changchang Xu; Lin Zhang; Ruru Sun; Ying Lv; Yan Liang; Feng Xu; Jiaojiao Pang; Yuguo Chen
Journal:  Front Pharmacol       Date:  2020-12-15       Impact factor: 5.810

Review 5.  IL-6 signalling pathways and the development of type 2 diabetes.

Authors:  Mohamad Akbari; Vahideh Hassan-Zadeh
Journal:  Inflammopharmacology       Date:  2018-03-05       Impact factor: 4.473

6.  Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma.

Authors:  Xingnan Li; Annette T Hastie; Michael C Peters; Gregory A Hawkins; Wanda Phipatanakul; Huashi Li; Wendy C Moore; William W Busse; Mario Castro; Serpil C Erzurum; Benjamin Gaston; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Sally E Wenzel; Deborah A Meyers; John V Fahy; Eugene R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2019-09-09       Impact factor: 10.793

Review 7.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

Review 8.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

Review 9.  Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.

Authors:  Isabelle Amigues; Alexander H Pearlman; Aarat Patel; Pankti Reid; Philip C Robinson; Rashmi Sinha; Alfred Hj Kim; Taryn Youngstein; Arundathi Jayatilleke; Maximilian Konig
Journal:  Expert Rev Clin Immunol       Date:  2020-11-25       Impact factor: 4.473

10.  Inflammatory Markers and Incidence of Hospitalization With Infection in Chronic Kidney Disease.

Authors:  Junichi Ishigami; Jonathan Taliercio; Harold I Feldman; Anand Srivastava; Raymond Townsend; Debbie L Cohen; Edward Horwitz; Panduranga Rao; Jeanne Charleston; Jeffrey C Fink; Ana C Ricardo; James Sondheimer; Teresa K Chen; Myles Wolf; Tamara Isakova; Lawrence J Appel; Kunihiro Matsushita
Journal:  Am J Epidemiol       Date:  2020-05-05       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.